QuantRx Biomedical Corporation

QuantRx Biomedical Corporation

QTXB
QuantRx Biomedical CorporationUS flagOther OTC
0.00
USD
+0.00
- -
118,045.00Market Cap
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
TTM
Revenue per Share
0.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.07
0.01
-0.02
-0.01
-0.01
-0.01
-0.01
-0.01
0.01
-0.01
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
-0.03
-0.04
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.09
-1.06
-1.02
-0.97
-0.93
-0.85
-0.75
-0.68
-0.63
-0.64
-0.65
-0.65
-0.66
-0.66
Tangible Book Value per Share
- -
0.01
- -
-0.01
-0.02
-0.02
-0.02
-0.03
-0.01
-0.02
-0.03
-0.03
-0.03
-0.04
Basic Weighted Avg Shares
44
44
47
50
53
59
67
74
79
79
79
79
79
79
Sales/Revenue/Turnover
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-94.23
-3,148.41
-4,174.82
-3,244.21
-6,166.55
-19,032.18
-229,941.67
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-3
1
-1
-1
- -
-1
- -
- -
1
-1
-1
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-123.6
1,304.5
-4,105.93
-4,712.31
-5,861.79
-34,032.3
-299,858.97
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
-1
-1
-1
-2
-2
-1
-2
-2
-2
-3
-3
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
-1
-1
-1
-2
-1
-2
-2
-2
-3
-3
Return on Invested Capital (%)
- -
-768.07
- -
- -
- -
- -
- -
- -
-27.26
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-1.77
- -
- -
- -
- -
- -
- -
-2.31
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Mar'22
Jun'22
Sep'22
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
79
79
79
Market Capitalization
- -
- -
- -

Working Capital

FRC

in mil. unless spec.
Mar'22
Jun'22
Sep'22
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
3
Payables & Accruals
- -
- -
- -
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-7.83%
21.94%
10.92%
Free Cash Flow
-5.2%
1.97%
-33.96%
Net Income, GAAP
-56.13%
-115.05%
2.89%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Shalom Z. Hirschman
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Address
10190 SW 90th Avenue Tualatin OR United States of America 97062
IPO Date
Jul 2, 2004
Business
QuantRx Biomedical Corporation (OTCQX: QTXB) develops and commercializes innovative medical devices for women's health, focusing on minimally invasive solutions for gynecological conditions. The company offers the FDA-cleared Paradigm Shaped Tissue Punch, a single-use disposable device for precise endometrial biopsy sampling; the Pap-Gen device for cervical sample collection in Pap smear testing; and related biopsy instruments and kits designed to improve diagnostic accuracy and patient comfort. These products target healthcare providers in obstetrics, gynecology, and pathology, with distribution primarily in North America and select international markets. Founded in 2000 and headquartered in Cleveland, Ohio, QuantRx operates in the medical device segment of the healthcare industry, serving clinics, hospitals, and diagnostic laboratories. In recent developments, the company delisted from Nasdaq and transitioned to OTCQX trading under QTXB in 2023 to enhance operational flexibility; it also expanded its product pipeline with advancements in shaped biopsy technologies and pursued strategic partnerships for global commercialization within the last two years.